new version V2017

Exenatide antidiabetic drugs

AC 2993 - Byetta - AC 2993 LAR - exendin 4 - Ex4 peptide - exendin-4 - bydureon - exenatide      

pdf
TrialStudied treatmentControl treatmentpatientsROBResultNCT

diabetes type 2

Buse 10µg/d, 2004exenatide 10µg/dplacebo (add on SU)Negative NCT00039026
Buse 20µg/d, 2004exenatide 20µg/dplacebo (add on SU) -
Heine, 2005exenatide 20µg/dinsulin (add on SU+MET)Negative
DeFronzo 10µg/d, 2005exenatide 10µg/dplacebo (add on MET) Low risk of bias Negative NCT00039013
DeFronzo 20µg/d, 2005exenatide 20µg/dplacebo (add on MET)SuggestingNCT00039013
Kendall 20µg/d, 2005exenatide 20µg/dplacebo (add on SU+MET) Low risk of bias Suggesting NCT00035984
Kendall 10µg/d, 2005exenatide 10µg/dplacebo (add on SU+MET) Low risk of bias Negative NCT00035984
Davis, 2007exenatide 20µg/dinsulin (add on SU/MET) Risk of bias Negative NCT00099333
Barnett, 2007exenatide 20µg/dinsulin (add on SU/MET) Exploratory Suggesting NCT00099619
Nauck, 2007exenatide 20µg/dinsulin BIAsp twice daily add on SU+MET Risk of bias Negative NCT00082407
Kim, 2007exenatide weeklyplacebo (add on MET) Exploratory NegativeNCT00103935
Zinman 20µg/j, 2007exenatide 20µg/dplacebo (add on TZD+/-MET)Suggesting NCT00099320
Moretto (DOUBLONS avec druker), 2008exenatide other dosesplaceboNegativeNCT00381342
Gao, 2009exenatide 20µg/dplacebo (add on MET+/-SU) Low risk of bias Suggesting NCT00324363
Kadowaki (trial 8683), 2009exenatide 10µg/dplacebo (add on SU+/-MET/TZD) Exploratory Negative
DURATION-3 (Diamant), 2010exenatide weeklyinsulin glargine Risk of bias Suggesting NCT00641056
DURATION-2 (Bergenstal) (vs pioglitazone), 2010exenatide weeklypioglitazoneSuggestingNCT00637273
DURATION-2 (Bergenstal) (vs sitagliptin), 2010exenatide weeklysitagliptin Exploratory SuggestingNCT00637273
Buse, 2011exenatide 20µg/dplacebo (add on insulin) Low risk of bias Negative NCT00765817
EXSCEL, 2017exenatideplacebo Low risk of bias ConclusiveNCT01144338
H8O-MC-GWDE ongoing exenatide weeklyliraglutide - NCT01029886